Why focal hip cartilage defects need a deliberate treatment choice

Being told you have a focal cartilage defect in your hip joint — and that it is not yet full osteoarthritis — leaves many patients in a genuinely uncertain position: real symptoms, real structural damage, but no obvious next step between physiotherapy and a hip replacement.

A focal Grade III or IV cartilage defect means the damage is confined to a defined area of the joint surface, penetrating through most or all of the cartilage layer but leaving the surrounding tissue relatively intact. This is meaningfully different from the diffuse, whole-joint wear of end-stage osteoarthritis. Because the lesion is localised, targeted repair strategies remain viable — but only if addressed before the defect enlarges and the surrounding cartilage begins to fail.

The hip joint's anatomy makes this more complex than equivalent defects in the knee or shoulder. The deep ball-and-socket configuration places the femoral head cartilage in a confined space under full body weight. Accessing that surface — whether to inject a scaffold or to implant a graft — demands precision that other joints do not require to the same degree. Congruency between any repair and the surrounding native cartilage matters enormously in a joint that transmits load with every step.

Common causes of focal hip defects include femoroacetabular impingement (FAI), direct trauma, and repetitive loading; age-related wear accounts for only part of the picture. Cartilage itself has negligible capacity for self-repair, so untreated focal defects tend to progress rather than stabilise.

For suitable patients, two structurally distinct interventions now exist: a ChondroFiller injection — an ultrasound-guided outpatient collagen scaffold procedure — and hip OATS (Osteochondral Autograft Transfer System), a surgical graft operation. This article compares them.

What ChondroFiller injection involves

ChondroFiller injection is delivered in an outpatient hip clinic under real-time ultrasound guidance, using local anaesthesia. There is no surgical dislocation, no operating theatre, and no general anaesthetic — the entire procedure takes place as a clinic appointment.

The product itself is an acellular Type I purified collagen hydrogel, CE-marked as a Class III medical device and manufactured by Meidrix Biomedicals GmbH in Germany. It contains no donor cells and no biological material that needs to be harvested from the patient beforehand. Once injected precisely into the focal defect, the collagen solution gels at body temperature, forming a stable three-dimensional scaffold directly over the damaged surface.

From that point, the body's own biology takes over. Progenitor cells present in the surrounding synovium and subchondral bone migrate into the matrix — ex vivo work using human osteochondral tissue has confirmed that active cell recruitment begins within approximately the first two weeks of contact. Over the following three to six months, those recruited cells progressively remodel the scaffold into fibrocartilage-like repair tissue while the original collagen matrix naturally resorbs. This process is known as matrix-induced chondrogenesis.

The approach is additive rather than subtractive: the scaffold fills the defect from the top down, cushioning the worn surface without removing surrounding tissue — a meaningful contrast to surgical procedures that require debridement of the joint bed before any repair material can be placed.

Because no surgery is involved, patients who are unsuitable for general anaesthesia or hip surgery remain eligible. No published age ceiling exists for the injection route, and the scaffold has been used for defects up to 6 cm². A 2021 prospective cohort by Perez-Carro et al. (26 patients, JHPS) demonstrated ChondroFiller to be viable for full-thickness acetabular defects with promising short-term results. Long-term hip-specific evidence beyond this cohort has not yet been established, and further follow-up data are needed.

What hip OATS surgery involves

Hip OATS takes a structurally different approach: rather than laying a scaffold over the worn surface, it replaces the damaged tissue with a cylindrical plug of native cartilage and underlying bone.

The plug is harvested from a non-weight-bearing donor area — typically the ipsilateral knee — and press-fitted into the prepared femoral head defect to recreate a congruent articular surface composed mainly of hyaline cartilage alongside its supporting subchondral bone. Hyaline cartilage is mechanically more durable than the fibrocartilage-like tissue produced by regenerative approaches. Harvest carries a meaningful risk of donor-site discomfort or stiffness at the knee, which is a practical consideration for patients choosing between options.

Surgical access presents a significant challenge specific to the hip. Most hip OATS procedures require the femoral head to be dislocated under general anaesthesia — an additional step not needed for the equivalent knee operation. An arthroscopic-assisted retrograde technique has been reported: one published case demonstrated full pain-free range of motion and near-complete graft incorporation at 26 months without dislocation, though this approach remains less common and demands specialist hip-preservation experience.

Patient selection is narrow. The procedure is generally reserved for active patients under 50 with contained focal lesions smaller than approximately 3 cm²; diffuse osteoarthritis — specifically Tönnis Grade 2–3 — is a documented negative predictor. Modified Harris Hip Scores typically improve from the low-to-mid 40s pre-operatively to the upper 70s–80s post-operatively.

On long-term survivorship, a Bone & Joint review confirmed graft survival of approximately 85–96% at two years, declining to 60–78% at five to ten years. Whilst most patients eventually require conversion to total hip arthroplasty, over half of grafts survive beyond ten years — evidence that OATS functions as a viable time-buying preservation strategy rather than a permanent solution.

How the evidence compares — and where the gaps are

No trial has directly compared ChondroFiller injection with hip OATS in the same patient population. The comparative picture below is built from separate single-arm series and a pooled safety analysis — directional confidence is moderate rather than definitive.

For ChondroFiller injection, a pooled series of approximately 30 patients reports a serious complication rate of approximately 0% and a reoperation rate of 3–8% for defects up to 6 cm², with symptom-relief success of 70–85% across published cases. Against microfracture as a historical comparator, those figures are favourable: published microfracture series have reported reoperation rates of up to 41%, alongside well-documented fibrocartilage breakdown at two to three years. Where the evidence base is thinner is on long-term cartilage-quality outcomes for the injectable route in the hip — studies beyond the 2021 cohort's follow-up window have not yet been published, and this remains the most significant current gap.

For hip OATS, the Bone & Joint 2023 survivorship review found graft survival of approximately 85–96% at two years, declining to 60–78% at five to ten years. Modified Harris Hip Scores improved from the low-to-mid 40s pre-operatively to the upper 70s–80s post-operatively. Survivorship and functional improvement are distinct measures, and the distinction is clinically meaningful: survivorship tracks whether the graft holds; functional scores track how patients move and feel. Together they suggest that suitable candidates can expect genuine functional gains across the working life of the graft — not simply a delay in decline — even if most eventually require conversion to hip arthroplasty.

Which patients suit each treatment

The practical decision between the two pathways rarely comes down to defect size alone. Several factors frequently point clearly towards one or the other — and some patients will be realistic candidates for only one of them regardless of their preference.

ChondroFiller injection tends to be the more practical route where fitness for general anaesthesia is a concern, where a recovery period extending to six to twelve months is not manageable, or where the defect sits in the acetabulum rather than on the femoral head — a location that makes surgical plug implantation particularly demanding. Patients with medical comorbidities, those whose work or caring responsibilities make an extended non-weight-bearing period difficult, and those who wish to avoid an operating theatre entirely are groups for whom the outpatient injection pathway is often worth exploring as a first step.

Hip OATS is more likely to be the recommendation when structural hyaline cartilage restoration is the priority — particularly in a younger, highly active patient with a small, contained femoral head lesion where the case for a durable bone-and-cartilage graft outweighs the burden of surgery and rehabilitation.

Neither pathway is appropriate where diffuse joint disease has overtaken the entire hip surface; both require meaningful residual cartilage and bone stock to be viable. Confirming this through specialist imaging is the essential prerequisite: an MRI assessment of defect size, location, and cartilage grade is needed before concluding which option is feasible for an individual patient. Open MRI is available for patients in whom standard closed-bore imaging is not suitable.

Lincolnshire Hip is part of the MSK Doctors group and accepts patients without referral for hip assessment.

Recovery, risks, and getting assessed

Practical recovery differences are significant enough to influence the decision independently of clinical suitability — and they are worth setting out plainly before any assessment appointment.

ChondroFiller injection is an outpatient procedure with same-day discharge; no theatre recovery, no general anaesthetic to clear, and no surgical wound to manage. Activity restrictions during the early weeks while the scaffold integrates are modest. Benefits develop gradually over three to six months as the collagen matrix remodels into repair tissue. The pooled complaint rate from published cases is approximately 0.06%; without a surgical wound, donor site, or implanted graft, the infection and operative morbidity risks associated with surgical cartilage procedures do not apply.

Hip OATS carries a longer practical burden. The initial non-weight-bearing phase followed by a graduated rehabilitation programme means the full recovery arc typically runs to six to twelve months. The operative risks — at the plug harvest site and at the implanted graft — are real, and a detailed pre-operative conversation with the treating surgeon is essential before committing.

A sound assessment for either pathway starts with specialist review and appropriate hip imaging to establish defect grade, size, and subchondral bone status. Lincolnshire Hip is part of the MSK Doctors group and accepts patients without referral for hip assessment.

Neither treatment is a realistic option where diffuse end-stage osteoarthritis has overtaken the majority of the hip joint surface — and honest expectation-setting at the assessment stage matters as much as which procedure is ultimately chosen.